A Game-Changing Advocacy Story: Unlocking Access to Weight Loss Medication
In the world of healthcare, where access to treatment can be a matter of life-changing impact, Dr. Remon Eskandar's journey is an inspiring one. As a GP with specialized skills in obesity management, he has witnessed the power of medical intervention in transforming lives. But here's where it gets controversial: the cost of these life-changing medications often puts them out of reach for many.
Dr. Eskandar, a passionate advocate for health equity, has been instrumental in a successful campaign to have the weight-loss drug semaglutide (Wegovy) subsidized on the Pharmaceutical Benefits Scheme (PBS). Practicing at the Bendigo Healthy Weight Clinic, he has seen patients gain control over their obesity, leading to improved health, increased ability to exercise, and a better quality of life.
"Our patients are finally living their lives to the fullest," Dr. Eskandar shares. "They're enjoying social activities and reducing future health risks. It's a daily occurrence for those who've struggled for years with no success."
However, the annual cost of Wegovy, around $4500, is a luxury for most. "It shouldn't be this way," Dr. Eskandar emphasizes. "Our patients are doing everything right, but their biology fights against them. Private scripts can cost up to $800 per month, creating a massive health divide."
Determined to bridge this gap, Dr. Eskandar took action. Along with fellow GPs, he developed a health equity statement and communicated directly with the health minister's office. Their message was clear: obesity is a chronic, complex disease, not a lifestyle choice. Investing in PBS listing would prevent future costs related to obesity-related conditions.
The Australian Institute of Health and Welfare estimates that 66% of adults were overweight or obese in 2022. Knowing the ongoing cost of subsidizing weight-loss drugs, Dr. Eskandar suggested focusing on a target group of high-risk patients with cardiovascular disease and severe obesity.
"We started with a controlled condition, where we could define the criteria and convince the government," he explains. "The data shows improved health conditions for these patients, reducing cardiovascular complications and healthcare costs by avoiding hospitalization."
And it worked. The Pharmaceutical Benefits Advisory Committee (PBAC) recommended Wegovy's inclusion on the PBS for patients who have experienced a cardiovascular event. The Federal Health Minister is now working with the manufacturer, Novo Nordisk, on the next steps.
"Our advocacy has led to tangible progress," Dr. Eskandar says. "For those who couldn't afford it, the financial barrier is removed, helping them sustain weight loss and reduce cardiovascular events."
But Dr. Eskandar isn't stopping here. He believes there's evidence to fund Wegovy and similar medications for other conditions, including liver disease, renal issues, osteoarthritis, and obstructive sleep apnea.
"GPs are uniquely positioned to advocate," he asserts. "We see the real-world impact of policy decisions on our patients. When we unite, we can drive change that improves lives directly."
And this is the part most people miss: one GP may be one doctor, but together, they are a powerful movement.
What do you think? Should more weight-loss medications be funded on the PBS? Share your thoughts in the comments!
